Waylis Therapeutics LLC
Privately held: no public share price
Assets
(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptorSmall molecule | Epilepsy | |
| Approved | Ribonucleotide reductaseSmall molecule | Sickle Cell Disease | |
| Approved | Triglyceride metabolismSmall molecule | Severe Hypertriglyceridemia | |
Rabeprazole(Aciphex) | Approved | H+/K+-ATPase (gastric proton pump)Small molecule | Helicobacter pylori Infection |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.